名古屋大学 · 医学
Fumiharu Ohka教授の研究室は、脳腫瘍、特に膠腫瘍（glioma）および髄膜腫瘍（meningioma）の病態メカニズムを解明することを目的としています。特に、治療抵抗性のメカニズムとしてのMGMTプロモーターのメチル化、がん幹細胞（GSCs）、血脳関門の役割、およびIDH状態に伴う腫瘍の分子的特徴に注目し、個別化医療に繋がる新規治療標的の同定を目指しています。最近では、脳腫瘍の三次元オルガノイドモデルの構築により、腫瘍微小環境や薬剤反応の解析を進めており、臨床応用に向けた基盤を強化しています。
Figures are computed from collected data and may differ slightly.
Glioblastoma multiforme (GBM) is one of the most frequently occurring tumors in the central nervous system and the most malignant tumor among gliomas. Despite aggressive treatment including surgery, adjuvant TMZ-based chemotherapy, and radiotherapy, GBM still has a dismal prognosis: the median survival is 14.6 months from diagnosis. To date, many studies report several determinants of resistance to this aggressive therapy: (1) O(6)-methylguanine-DNA methyltransferase (MGMT), (2) the complexity o
Gliomas are the most frequently occurring primary brain tumor in the central nervous system of adults. Glioblastoma multiformes (GBMs, WHO grade 4) have a dismal prognosis despite the use of the alkylating agent, temozolomide (TMZ), and even low grade gliomas (LGGs, WHO grade 2) eventually transform to malignant secondary GBMs. Although GBM patients benefit from promoter hypermethylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) that is the main determinant of resistance to TMZ, rec
An organoid model for meningioma enabled us to elucidate the tumor biology of meningioma along with potent treatment targets for meningioma.
Gliomas are classified by combining histopathologic and molecular features, including isocitrate dehydrogenase (<i>IDH</i>) status. Although <i>IDH</i>-wild-type diffuse astrocytic glioma (DAG) shows a more aggressive phenotype than <i>IDH</i>-mutant type, lack of knowledge regarding relevant molecular drivers for this type of tumor has hindered the development of therapeutic agents. Here, we examined human <i>IDH</i>-wild-type DAGs and a glioma mouse model with a mosaic analysis with double mar
Open papers in the app to read, cite, and organize with AI.
